Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge 2026
Historical reference for the closed NIH TRDNT Challenge Phase I, which sought novel endogenous-RNA technologies and offered up to $500,000 in Phase I prizes; NIH lists later phases as anticipated rather than announced application rounds.
Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge 2026
Status: Phase I is closed. The NIH’s official challenge announcement gives July 15, 2026 as the Phase I submission end date. The dedicated challenge website now describes Phase II as “Coming Soon,” while the NIH announcement and Common Fund pages describe future phases as anticipated and subject to NIH discretion. No confirmed Phase II application deadline is published in the official materials reviewed for this update. This entry is therefore a historical reference for the completed Phase I, not an invitation to submit after the closing date.
What this opportunity was
The Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge was a prize competition run by the National Institutes of Health Common Fund Venture Program. It was not a conventional NIH grant, and Phase I did not provide research funding in installments. Participants proposed a new technology, and prize decisions were based on the submitted concept and its credible path toward later prototype development.
The scientific target was endogenous RNA in human disease. NIH was interested in tools that could make RNA a direct therapeutic target, especially for diseases caused by RNA dysfunction or by proteins that are difficult to address with small-molecule drugs. The aim was broader than proposing one treatment for one disease. A strong solution needed to show how a technology could support new RNA-targeted therapies across multiple diseases, with one disease or disease area potentially serving as a proof of concept.
Examples in the official scope included methods that alter RNA–RNA-binding-protein interactions to affect splicing, stability, or translation; ways to target long non-coding RNAs; assays for finding native RNA–protein interactions and measuring therapeutic effects; screening libraries enriched for RNA-targeting small molecules; and approaches that modify abnormal RNA structures. The list was illustrative rather than exhaustive. The central boundary was that the proposed solution had to target endogenous RNA in a way that could address human disease. A standard RNA-based therapeutic program, including mRNA vaccine development, was not automatically responsive merely because it involved RNA.
Phase I prize and later phases
The completed Phase I offered up to $500,000 in total prizes, with up to $20,000 per winner and a maximum of 25 winners. This was the prize amount relevant to the closed 2026 application window. NIH did not promise development funds or university overhead for preparing a submission, and the FAQ states that prize money is paid only to winners at the end of a challenge phase. Prize payments are made electronically and may be subject to federal income taxes.
NIH described a planned total of up to $13,100,000 across the three-phase concept: up to $500,000 for Phase I and up to $12,600,000 for the anticipated later phases. The additional amount was not a current award pool that applicants could claim. Phase II was described as Prototype Development and Use Case Demonstration, with an anticipated interim milestone of up to $120,000 per winner and a final Phase II prize of up to $320,000 per winner. Phase III was described as Final Iteration and Technology Dissemination, with up to $525,000 per winner and a possible runner-up award of up to $200,000.
The NIH announcement explicitly says that Phases II and III require later announcements, registration details, and requirements, and that their launch is discretionary and contingent on appropriated funds. The challenge website currently says “Phase II Coming Soon.” Its published planning information gives an anticipated Phase II launch in August 2026, a milestone submission window from November 2026 to January 2027, milestone winners in March 2027, a main submission window from June to July 2027, and final winners in October 2027. These are planning windows, not confirmed deadlines. Phase III is likewise presented as anticipated, with a launch in November 2027, a submission window from August to October 2028, and winners in January 2029. Readers should not treat any of those future windows as open until NIH publishes a new announcement and registration instructions.
Phase I timeline and current archive meaning
The official challenge website lists the Phase I submission window as May 29–July 15, 2026. The NIH announcement lists the submission opening as May 30, 2026 and the submission end as July 15, 2026. The difference in the opening-day display does not affect the verified closing date retained in this page’s metadata. The official schedule placed judging in July–August 2026 and winner announcements in August–September 2026 on the challenge website; the NIH announcement gives August 2026 for winner announcements.
Because the submission end has passed and no later phase has been announced as an active application round, this page uses historicalReference = true. The metadata keeps the genuine Phase I closing date, 2026-07-15, rather than replacing it with a sentence or an invented future deadline. That distinction lets readers understand which cycle the article documents without suggesting that the closed form is still available.
Who Phase I was for
The challenge could be entered by an individual, an independent team, or an entity. An eligible private entity had to be incorporated in the United States and maintain its primary place of business there. An individual, whether entering alone or as part of a group, had to be a U.S. citizen or permanent resident to receive a monetary prize. Non-U.S. citizens and non-permanent residents could participate as members of an otherwise eligible team, and their participation could be recognized, but they could not receive a monetary prize.
Participants had to be at least 18 years old, register through the official challenge site, and agree to the published eligibility and participation rules. A federal entity or a federal employee acting within the scope of employment could not participate as an eligible prize recipient. The rules also exclude HHS employees acting in a personal capacity. A federal employee outside HHS was directed to consult an agency ethics official before participating or accepting a prize. These provisions are more precise than a blanket statement that every person connected with government is barred.
Teams had to designate a Team Captain. The captain handled registration and communications and would receive the full prize payment for a winning team. An entity had to designate a Point of Contact; the prize would be paid to the entity, not to that individual. If federal grant, cooperative-agreement, or other-transaction funds were used in preparing the submission, the participant had to register as the awardee institution or organization and follow the applicable award terms. The NIH FAQ also says that a university applicant did not generally need to use an Authorized Organizational Representative unless the submission used federal award funds; in that situation, the institutional rules and the challenge requirements applied.
What a Phase I submission required
The completed Phase I was an ideation and planning stage. NIH did not expect an already validated product, and the FAQ says that a technology already under development or validation was a poor fit for Phase I and more appropriate for a possible Phase II. At the same time, the proposal needed enough technical detail to show that a prototype could be developed later.
The formal package had three parts:
- Title and executive summary. The summary had to briefly describe the technology and explain how it could help develop novel RNA-targeted therapies across multiple diseases. NIH warned participants not to include proprietary or confidential information in the title or executive summary because those portions could be made public if a participant won a prize.
- Written proposal, limited to 10 pages. The proposal had to describe the significant patient or health need, explain the early-stage technical concept for targeting RNA, and give a detailed development and use-case plan. It also needed to describe the team’s expertise and environment, or how missing resources could be acquired quickly, and identify likely roadblocks with ways to address them.
- References. A separate reference page was required and did not count toward the 10-page proposal limit.
The proposal was not a standard R01-style application. A budget was not required, and the FAQ says preliminary data were not required, although participants could include preliminary data when needed to support the solution. The strongest package would have connected the scientific idea to a significant unmet need, explained why the approach was novel rather than an established method, showed a plausible route to a working prototype, and demonstrated that the team could handle technical setbacks.
How participants entered
The first step was to read the NIH announcement, eligibility rules, participation rules, and submission guidance. The second was registration at trdntchallenge.com, where the participant identified whether the entry was from an individual, independent team, or entity and supplied the names, affiliations, and contact details required for the chosen structure. Registration also required an acknowledgment about whether federal funding would be used in developing the submission.
After registration, the participant assembled the Phase I package described above and submitted it through the challenge process during the closed May–July 2026 window. The proposal needed to focus on a novel technology rather than an already developed therapeutic, and it needed to explain how the concept could become a prototype in a later phase. A team also needed agreement about the Team Captain’s role and prize payment; an entity needed the correct Point of Contact and any required institutional approvals.
The official rules also addressed intellectual property and public disclosure. Participants retained their other intellectual-property rights, but participation granted NIH a paid-up, royalty-free, nonexclusive worldwide license to reproduce, publish, post, link to, share, and publicly display the submission. Since the title and executive summary could be posted publicly for winners, those sections needed to exclude confidential details. A prospective future applicant should review the later phase announcement rather than assume Phase I’s forms, eligibility details, or submission format carry forward unchanged.
How Phase I was judged
NIH described a technical expert review followed by federal judging and final programmatic decisions. The scoring categories were completeness of the requested information, potential clinical impact, novelty, and the likelihood that the participant could carry out development. Clinical impact considered unmet needs and applicability across disease areas. Novelty considered whether the technology was comprehensive and innovative and whether the proposal gave enough detail to judge future prototyping. Feasibility considered workflow, expertise, resources, roadblocks, and proposed solutions.
That structure explains why a broad promise about RNA therapeutics would not be enough. The entry needed a defined mechanism or technology class, a disease-relevant reason for the work, a path that could be tested in a later prototype phase, and a realistic account of what the team could do. It also needed to make clear how the eventual technology could become publicly available, because public dissemination is a stated goal of the overall challenge.
What to do now
There is no Phase I application to submit after July 15, 2026. Readers interested in a later opportunity should monitor the official NIH announcement and the challenge site for a formal Phase II launch, registration instructions, eligibility rules, and a new submission deadline. The challenge site’s “Phase II Coming Soon” notice and the NIH page’s anticipated August 2026 timing are signals to monitor, not confirmation that an application window is open. Do not use the anticipated August 2026 launch or any later planning window as a current deadline.
The authoritative starting points are the NIH TRDNT Challenge announcement, the NIH Common Fund TRDNT page, the TRDNT FAQ, the NIH funding-opportunities page, and the official challenge registration site. The NIH announcement remains the governing source for rules and prize terms; the registration site is the place to watch for the next phase’s operational instructions.